Axim Biotechnologies Inc (OTCQB:AXIM)
| 0.60 Delayed Data As of Sep 24 |  -0.005 / -0.83%Today’s Change | 0.39 Today|||52-Week Range 1.22 | +38.63% Year-to-Date |
| SECTOR Industrial Services | INDUSTRY Environmental Services | MARKET CAP $80.0M |
Company Description
AXIM Biotechnologies, Inc. operates as a biotechnology company. It focuses in the research, development and production of pharmaceutical, nutraceutical, cosmetic and genetically controlled botanical products. The firm also involves in the extraction and purification of cannabinoids technologies based on its proprietary technologies. Its products include CBD-based controlled release chewing gum under CanChew brand and a combination of CBD and THC gum that treats pain and spasticity associated with multiple sclerosis under MedChew Rx brand. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
Contact Information
AXIM Biotechnologies, Inc. 6191 Cornerstone Court East San Diego California 92121 |
Employees
Shareholders
| Individual stakeholders | 30.53% |
| Mutual fund holders | -- |
| Other institutional | -- |
Top Executives
| John W. Huemoeller | President, Chief Executive Officer & Director |
| Robert T. Malasek | Chief Financial Officer & Secretary |
| Joseph Tauber | Chief Medical Officer |
| Jeffrey A. Busby | Senior Vice President-Business Development |
